Why the study?
Does high-dose heparin inhibit platelet accumulation in vivo?
Does high-dose heparin inhibit platelet accumulation in vivo?
High doses of heparin inhibit platelet accumulation induced by ADP, collagen, or PAF-acether in vivo, though the mechanism remains unclear and clinical relevance requires further study.
Answers are grounded in this paper and cite their sources.
High-dose heparin antiplatelet effects remain preclinical; leaves open human translation and does not alter current practice.
In vivo platelet aggregation has been studied using a novel, minimally invasive technique. No aggregatory effects of heparin were observed on normal circulating platelets nor was there enhancement of aggregation of platelets during activation by intravenous injection of ADP, collagen, PAF acether or thrombin. On the contrary, high doses of heparin were found to inhibit platelet accumulation induced by ADP, collagen or PAF-acether. Inhibition of these responses necessitated doses of heparin in excess of those required for anti-coagulant effects. The present experiments do not establish a mechanism for such inhibition. Extension to other species, including man, is needed before attributing clinical relevance to the present observations.
No takes yet. Share an insight, caveat, or question.
Barrett et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: